Benzinga | Dec 10, 2021 05:41AM EST

Needham Maintains Buy on KalVista Pharmaceuticals, Lowers Price Target to $48

Needham analyst Serge Belanger maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy and lowers the price target from $50 to $48.